Scarica l'app Stockscreener
3.71
0.27%
0.010
Liminatus Pharma Inc Borsa (LIMN) Ultime notizie
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com UK
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
Liminatus Pharma moves Nasdaq listing to Capital Market tier - Bitget
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointMonthly Profile - dars.gov.et
Liminatus Pharma Warrants (LIMNW) Hold Flat at $0.07 as Narrow Range Defines TradingPrice Target - dars.gov.et
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan - The Globe and Mail
Liminatus Pharma Warrants (LIMNW) Remain Flat at $0.06 as Key Levels ConvergeCalendar Spread Trade - dars.gov.et
Liminatus Pharma, Inc. Primary Exchange Listing has Changed to Nasdaq Capital Market from Nasdaq Global Market - marketscreener.com
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
Liminatus Pharma Warrants (LIMNW) Hold Steady at $0.04 – Flat Trading Signals ConsolidationBackspread Trade - vinanet.vn
Liminatus Pharma Inc. (LIMN) Edges Higher as Stock Tests Key Resistance LevelETF Creation Redemption - dars.gov.et
LIMN|Liminatus Pharma Ord Shs Class A|Price:0.119|Chg%:+0.002 - TradingKey
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMNW - TradingView
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split - The Globe and Mail
Liminatus Pharma, Inc. Revenue Breakdown – BOATS:LIMN - TradingView
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Frontier tech research, news & data - MLQ.ai
Liminatus Pharma Warrants (LIMNW) Edge Higher: A Closer Look at the $0.06 LevelEarnings Breakout Stocks - dars.gov.et
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) Plunges 16.72% as Key Support Nears $0.11PCR Mean Reversion - vinanet.vn
Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Enterprise value to EBIT forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) - Moomoo
Liminatus Pharma Warrants Plunge 36%: Key Levels and Outlook for LIMNWZero Lag EMA - vinanet.vn
Curious about the most active stocks on Thursday? - ChartMill
Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session - Sahm
Form 13D/A Liminatus Pharma For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Liminatus Pharma Inc For: 14 July By Investing.com - Investing.com Nigeria
Liminatus Pharma (LIMN) investors Valetudo and Chris Kim report 9.6M-share stake - Stock Titan
Liminatus Pharma Warrants (LIMNW) Hold Steady at $0.05 in Stagnant TradingLong Short Pair - dars.gov.et
Form DEF 14A Liminatus Pharma Inc For: 13 July By Investing.com - Investing.com Nigeria
Enterprise value to EBIT forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Price to sales forward of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
Liminatus Pharma(LIMN) Stock Options Chain | Quotes & News - Moomoo
Liminatus Pharma (LIMN) Slides 7.3% to $0.11, Testing Key Support at $0.10Standard Deviation - dars.gov.et
Enterprise value to EBIT forward of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
Number of employees of Liminatus Pharma, Inc. – NASDAQ:LIMNW - TradingView
Liminatus Pharma (LIMN) Retreats 6.3% to $0.12, Approaching Key Support LevelHigh Yield Stocks - dars.gov.et
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):